JP2019529500A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529500A5 JP2019529500A5 JP2019517777A JP2019517777A JP2019529500A5 JP 2019529500 A5 JP2019529500 A5 JP 2019529500A5 JP 2019517777 A JP2019517777 A JP 2019517777A JP 2019517777 A JP2019517777 A JP 2019517777A JP 2019529500 A5 JP2019529500 A5 JP 2019529500A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- group
- alkyl
- compound according
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 201000011510 cancer Diseases 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 239000011780 sodium chloride Substances 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 6
- -1 hydrate Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 4
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010017758 Gastric cancer Diseases 0.000 claims 2
- 208000007766 Kaposi Sarcoma Diseases 0.000 claims 2
- 206010024324 Leukaemias Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 102100017063 NT5E Human genes 0.000 claims 2
- 101710039712 NT5E Proteins 0.000 claims 2
- 206010025310 Other lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000649 Small Cell Carcinoma Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 201000005216 brain cancer Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000002029 Allergic Contact Dermatitis Diseases 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 208000007502 Anemia Diseases 0.000 claims 1
- 208000003017 Aortic Valve Stenosis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 229950002916 Avelumab Drugs 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 210000004252 Chorionic Villi Anatomy 0.000 claims 1
- 206010009887 Colitis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 229950009791 Durvalumab Drugs 0.000 claims 1
- 208000005679 Eczema Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 210000000265 Leukocytes Anatomy 0.000 claims 1
- 206010025135 Lupus erythematosus Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010019706 Nivolumab Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 206010038038 Rectal cancer Diseases 0.000 claims 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010038435 Renal failure Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 108010072668 atezolizumab Proteins 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 108010010826 avelumab Proteins 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000006233 congestive heart failure Diseases 0.000 claims 1
- 201000010918 connective tissue cancer Diseases 0.000 claims 1
- 201000004624 dermatitis Diseases 0.000 claims 1
- 231100000080 dermatitis contact Toxicity 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 108010016436 durvalumab Proteins 0.000 claims 1
- 231100001003 eczema Toxicity 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatoms Chemical group 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulators Drugs 0.000 claims 1
- 230000001506 immunosuppresive Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000002077 muscle cancer Diseases 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 108010026276 pembrolizumab Proteins 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000010208 seminoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 201000009594 systemic scleroderma Diseases 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000006704 ulcerative colitis Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 0 *c1ccccc1C1(CC1)Nc1c(C=NC(C2C3)C2=C([C@@]2O)OC(C4)(C4OCPO)[C@@]2O)c3nc(Cl)n1 Chemical compound *c1ccccc1C1(CC1)Nc1c(C=NC(C2C3)C2=C([C@@]2O)OC(C4)(C4OCPO)[C@@]2O)c3nc(Cl)n1 0.000 description 2
Images
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022158467A JP2022173493A (ja) | 2016-10-03 | 2022-09-30 | アデノシン5’-ヌクレオチダーゼの阻害剤 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662403598P | 2016-10-03 | 2016-10-03 | |
US62/403,598 | 2016-10-03 | ||
PCT/US2017/054694 WO2018067424A1 (en) | 2016-10-03 | 2017-10-02 | Inhibitors of adenosine 5'-nucleotidase |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022158467A Division JP2022173493A (ja) | 2016-10-03 | 2022-09-30 | アデノシン5’-ヌクレオチダーゼの阻害剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019529500A JP2019529500A (ja) | 2019-10-17 |
JP2019529500A5 true JP2019529500A5 (US20040106767A1-20040603-C00005.png) | 2021-04-15 |
JP7184761B2 JP7184761B2 (ja) | 2022-12-06 |
Family
ID=61831914
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019517777A Active JP7184761B2 (ja) | 2016-10-03 | 2017-10-02 | アデノシン5’-ヌクレオチダーゼの阻害剤 |
JP2022158467A Withdrawn JP2022173493A (ja) | 2016-10-03 | 2022-09-30 | アデノシン5’-ヌクレオチダーゼの阻害剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022158467A Withdrawn JP2022173493A (ja) | 2016-10-03 | 2022-09-30 | アデノシン5’-ヌクレオチダーゼの阻害剤 |
Country Status (6)
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11058704B2 (en) | 2016-10-03 | 2021-07-13 | Arcus Biosciences, Inc. | Inhibitors of adenosine 5′-nucleotidase |
US20200115404A1 (en) * | 2017-03-31 | 2020-04-16 | Peloton Therapeutics, Inc. | Cd73 inhibitors and uses thereof |
US11129841B2 (en) | 2017-05-10 | 2021-09-28 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
CN111094317B (zh) * | 2017-12-29 | 2023-03-31 | 上海和誉生物医药科技有限公司 | 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用 |
CN112004541A (zh) * | 2018-03-09 | 2020-11-27 | 艾库斯生物科学有限公司 | 肠道外给药的免疫增强药物 |
TW202014182A (zh) | 2018-04-30 | 2020-04-16 | 美商歐瑞克製藥公司 | Cd73抑制劑 |
WO2020047082A1 (en) * | 2018-08-28 | 2020-03-05 | Eternity Bioscience Inc. | Cd73 inhibitors and therapeutic uses thereof |
AU2020205753A1 (en) | 2019-01-11 | 2021-08-05 | Omeros Corporation | Methods and compositions for treating cancer |
WO2020151707A1 (zh) * | 2019-01-22 | 2020-07-30 | 江苏恒瑞医药股份有限公司 | 一种新型的小分子cd73抑制剂、其制备方法及其在医药上的应用 |
EP3939988A4 (en) * | 2019-03-20 | 2022-08-24 | Korea Research Institute of Chemical Technology | PHARMACEUTICAL COMPOSITION WITH NOVEL HETEROCYCLIC AZOLOPYRIMIDINE COMPOUND AS THE ACTIVE SUBSTANCE |
EP3947463A4 (en) * | 2019-03-29 | 2022-12-21 | Arcus Biosciences, Inc. | TREATMENT OF CANCER USING AN IDENTIFIED ADENOSINE FINGERPRINT |
WO2020210970A1 (en) * | 2019-04-16 | 2020-10-22 | Bioardis Llc | Imidazotriazine derivatives as cd73 inhibitors |
TWI821559B (zh) * | 2019-04-28 | 2023-11-11 | 大陸商上海和譽生物醫藥科技有限公司 | 一種cd73抑制劑,其製備方法和應用 |
WO2020252380A2 (en) | 2019-06-14 | 2020-12-17 | Southern Research Institute | 2,4,7-substituted-7-deaza-2'-deoxy-2'-fluoroarabinosyl nucleoside and nucleotide pro-drugs and uses thereof |
EP3999517A4 (en) * | 2019-07-16 | 2023-07-12 | Oric Pharmaceuticals, Inc. | CD73 INHIBITORS |
WO2021040356A1 (en) * | 2019-08-23 | 2021-03-04 | Kainos Medicine, Inc. | C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition |
JP7544815B2 (ja) * | 2019-10-30 | 2024-09-03 | オリック ファーマシューティカルズ,インク. | Cd73阻害剤 |
IL295569A (en) | 2020-03-19 | 2022-10-01 | Arcus Biosciences Inc | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
PE20231078A1 (es) | 2020-06-02 | 2023-07-17 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
EP4341262A1 (en) | 2021-05-21 | 2024-03-27 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
WO2022246177A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl compounds |
EP4423069A1 (en) | 2021-10-29 | 2024-09-04 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2023215719A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
CN117321066A (zh) * | 2022-07-12 | 2023-12-29 | 南京工业大学 | 一种基于虫草素经衍生化具有抗肿瘤效应的化合物 |
CN116768949A (zh) * | 2022-07-12 | 2023-09-19 | 南京工业大学 | 一种基于3’-脱氧腺苷经化学修饰改性的具有抗癌效应的化合物 |
US20240124490A1 (en) | 2022-07-15 | 2024-04-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
TW202421150A (zh) | 2022-09-14 | 2024-06-01 | 美商阿克思生物科學有限公司 | 艾魯美冷之分散體 |
WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0468119A1 (en) * | 1990-07-24 | 1992-01-29 | Merrell Dow Pharmaceuticals Inc. | Novel carbocyclic analogs of certain nucleosides |
US6617439B1 (en) * | 2000-06-09 | 2003-09-09 | Bar-Ilan University | C8-substituted purine nucleotide analogs |
WO2004096233A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates |
MX2007006961A (es) * | 2004-12-10 | 2007-10-04 | Univ Emory | Analogos nucleosidos de ciclobutilo 2' y 3'-sustituidos para el tratamiento de infeccciones virales y proliferacion celular anormal. |
WO2006130217A2 (en) | 2005-04-01 | 2006-12-07 | The Regents Of The University Of California | Substituted phosphate esters of nucleoside phosphonates |
EP2021350B1 (en) * | 2006-03-21 | 2016-12-21 | Rheinische Friedrich-Wilhelms-Universität Bonn | Phosphorylated a2a receptor agonists |
CN101528260A (zh) * | 2006-10-26 | 2009-09-09 | 协和发酵麒麟株式会社 | 肠易激综合症治疗剂 |
WO2008121261A2 (en) * | 2007-03-28 | 2008-10-09 | Vioquest Pharmaceuticals, Inc. | Prodrugs of triciribin suitable for treatment of tumors and cancer |
NZ630800A (en) * | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Methods of preparing substituted nucleotide analogs |
US9090697B2 (en) | 2013-03-15 | 2015-07-28 | Bayer Healthcare Llc | Methods for treating bleeding disorders |
JP6657182B2 (ja) | 2014-04-25 | 2020-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌治療用のcd73阻害剤としてのプリン誘導体 |
US11058704B2 (en) | 2016-10-03 | 2021-07-13 | Arcus Biosciences, Inc. | Inhibitors of adenosine 5′-nucleotidase |
US20200115404A1 (en) | 2017-03-31 | 2020-04-16 | Peloton Therapeutics, Inc. | Cd73 inhibitors and uses thereof |
-
2017
- 2017-10-02 US US16/338,975 patent/US11058704B2/en active Active
- 2017-10-02 WO PCT/US2017/054694 patent/WO2018067424A1/en unknown
- 2017-10-02 EP EP17858945.3A patent/EP3518934A4/en active Pending
- 2017-10-02 CN CN201780061650.9A patent/CN110049767B/zh active Active
- 2017-10-02 JP JP2019517777A patent/JP7184761B2/ja active Active
- 2017-10-03 TW TW106134280A patent/TWI781960B/zh active
-
2022
- 2022-09-30 JP JP2022158467A patent/JP2022173493A/ja not_active Withdrawn
-
2024
- 2024-04-08 US US18/629,820 patent/US20240285665A1/en active Pending